Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20127001 | 0.85 | ALDH1A1 (0.36) | CDK4CCND1 | |
| SCHEMBL28900900 | 0.81 | CDK4 (0.41) | CDK4CCND1 | |
| SCHEMBL2299575 | 0.77 | CDK4 (0.69) | CDK4CCND1 | |
| SCHEMBL2301318 | 0.77 | CDK4 (0.69) | CDK4CCND1 | |
| SCHEMBL2298840 | 0.76 | CDK4 (0.64) | CDK4CCND1 | |
| SCHEMBL29988033 | 0.76 | CDK4 (0.67) | CDK4CCND1 | |
| SCHEMBL1990321 | 0.76 | CDK4 (0.67) | CDK4CCND1 | |
| SCHEMBL2298483 | 0.74 | CDK4 (0.46) | CDK4CCND1 | |
| SCHEMBL19873283 | 0.73 | CDK4 (0.71) | CDK4CCND1 | |
| SCHEMBL21133431 | 0.73 | CDK4 (0.49) | CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308654-B2 | Preparation and use of kinase inhibitor | CHANGZHOU LONGTHERA PHARMACEUTICALS INC. (CN) | 2019-06-04 | — | — | US | disclosed |
| US-20180127419-A1 | PREPARATION AND USE OF KINASE INHIBITOR | CHANGZHOU LONGTHERA PHAMACEUTICALS INC (CN) | 2018-05-10 | — | — | US | disclosed |
| US-20180127419-A1 | PREPARATION AND USE OF KINASE INHIBITOR | CHANGZHOU LONGTHERA PHAMACEUTICALS INC (CN) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127419-A1 | PREPARATION AND USE OF KINASE INHIBITOR | MAP3K19, MAP3K20, MAP3K1 | CDK4 313/4885CCND1 1206/4885 |
| US-10308654-B2 | Preparation and use of kinase inhibitor | MAP3K19, MAP3K20, MAP3K1 | CDK4 313/4885CCND1 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.